Page last updated: 2024-08-24

triazoles and HIV

triazoles has been researched along with HIV in 37 studies

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (40.54)29.6817
2010's21 (56.76)24.3611
2020's1 (2.70)2.80

Authors

AuthorsStudies
Baker, CR; Fulco, PP; Porter, AM1
Chapman, D; Demarest, J; Dong, WW; Ellery, S; Harrigan, PR; Heera, J; Mo, T; Poon, AF; Swenson, LC; Valdez, H1
Kravchenko, AV1
Guo, J; Wu, Y; Xu, GG1
Cavarelli, M; Chiappetta, S; Cossarizza, A; De Battista, D; De Biasi, S; Galli, L; Lazzarin, A; Malnati, M; Nozza, S; Pensieroso, S; Pogliaghi, M; Ripa, M; Scarlatti, G; Tambussi, G1
Arroyo-Manzano, D; Blanco, JR; Bravo, I; Crespo, M; Garcia Del Toro, M; Herrero, C; Llibre, JM; Moreno, S; Pasquau, J; Rivero, A; Rojas-Liévano, JF1
Abad, MA; de Pablo-Bernal, RS; Genebat, M; Jiménez-Mejías, ME; Leal, M; Martínez, O; Pacheco, YM; Pulido, I; Raffi-El-Idrissi Benhia, M; Ruiz-Mateos, E1
Andrei, G; Boons, E; Daelemans, D; Jacquemyn, M; Landesman, Y; Neggers, JE; Nogueira, TC; Pannecouque, C; Shacham, S; Snoeck, R; Tamir, S; van den Oord, J; Vanstreels, E; Vercruysse, T1
Carcenac, R; Cazabat, M; Cuzin, L; Delobel, P; Izopet, J; Jeanne, N; Nicot, F; Raymond, S; Requena, M1
Basson, AE; Pelly, SC; Pribut, N; van Otterlo, WA; Veale, CG1
De Luna-Romero, M; Dominguez-Molina, B; Genebat, M; Gonzalez-Serna, A; Leal, M; Muñoz-Fernández, MA; Pacheco, YM; Ruiz-Mateos, E; Tarancon-Diez, L1
Dehaen, W; Hayat, MQ; Iram, S; Jana, S; Pannecouque, C; Thomas, J1
Bowers, SJ; Mitchell, RJ; Potchoiba, MJ; Schroeder, CM; Small, HF; Walker, DK1
Alcamí, J2
Arenzana-Seisdedos, F1
Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S1
Delgado, R1
Camacho, A; Genebat, M; Leal, M; Rivero, A1
Clotet, B; Clumeck, N; Fätkenheuer, G; Goodrich, J; Mayer, H; Saag, M; Sullivan, J; van der Ryst, E; Westby, M1
Balzarini, J; McGuigan, C; Mehellou, Y1
Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; León, JA; Muñoz-Fernández, MA; Pulido, I; Rivas, I; Ruiz-Mateos, E; Sánchez, B1
McKinnell, JA; Saag, MS1
Larue, V; Lecourt, T; Micouin, L; Moumné, R; Seijo, B; Tisné, C1
Poizot-Martin, I1
Abbate, I; Bartolini, B; Bruselles, A; Capobianchi, MR; Chillemi, G; Ippolito, G; Narciso, P; Nicastri, E; Rozera, G; Tommasi, C1
Abad, MA; Ferrando-Martinez, S; Garcia-Perganeda, A; Genebat, M; Gonzalez-Serna, A; Leal, M; Ruiz-Mateos, E1
Chan, PL; Jacqmin, P; Lavielle, M; McFadyen, L; Weatherley, B1
Anderson, DD; Ghosh, AK1
Cui, Y; Jin, C; Li, X; Wu, N1
Boesecke, C; Pett, SL1
Mugavero, MJ; Napolitano, LA; Nevin, CR; Raper, JL; Saag, MS; Tamhane, A; Wilkins, SA; Willig, JH1
Guo, J; Li, Z; Wu, Y; Zhou, Q1
D'Cruz, OJ; Uckun, FM1
Brunel, AS; Fraisse, T; Lechiche, C; Mauboussin, JM; Pinzani, V; Sotto, A1
Mao, C; Sudbeck, EA; Uckun, FM; Venkatachalam, TK1
Stephenson, J1

Reviews

13 review(s) available for triazoles and HIV

ArticleYear
[Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens].
    Terapevticheskii arkhiv, 2013, Volume: 85, Issue:11

    Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles

2013
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
    Current topics in medicinal chemistry, 2014, Volume: 14, Issue:13

    Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles; Virus Replication

2014
[Viral entry as therapeutic target. Current situation of entry inhibitors].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11

    Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization

2008
[Maraviroc efficacy in clinical studies on the development of the molecule].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles

2008
[Mechanisms of resistance and failure of treatment with maraviroc].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11

    Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; Genes, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Molecular Sequence Data; Multicenter Studies as Topic; Peptide Fragments; Receptors, CXCR4; Selection, Genetic; Treatment Failure; Triazoles; Virus Attachment; Virus Internalization

2008
[At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; Humans; Maraviroc; Membrane Fusion; Receptors, CXCR4; Salvage Therapy; Triazoles; Viral Load; Virus Attachment

2008
[Conclusions and perspectives. Maraviroc].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11

    Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Peptide Fragments; Receptors, CXCR4; Salvage Therapy; Selection, Genetic; Triazoles; Virus Attachment; Virus Internalization

2008
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
    Current opinion in HIV and AIDS, 2009, Volume: 4, Issue:6

    Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Peptide Fragments; Piperazines; Pyrimidines; Salvage Therapy; Triazoles; Virus Internalization

2009
[CCR5-antagonists: contribution of a new antiretroviral class to the management of HIV infection].
    Medecine et maladies infectieuses, 2010, Volume: 40, Issue:5

    Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Triazoles; Viral Tropism

2010
Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.
    Future medicinal chemistry, 2011, Volume: 3, Issue:9

    Topics: Furans; Heterocyclic Compounds; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Pyrans; Structure-Activity Relationship; Triazoles

2011
Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.
    Current opinion in HIV and AIDS, 2012, Volume: 7, Issue:5

    Topics: Antibodies, Monoclonal; Antiviral Agents; CCR5 Receptor Antagonists; Coinfection; Cyclohexanes; Hepatitis C, Chronic; HIV; HIV Antibodies; HIV Infections; Humans; Maraviroc; Molecular Diagnostic Techniques; Triazoles; Viral Tropism; Virology

2012
Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Journal of enzyme inhibition and medicinal chemistry, 2006, Volume: 21, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anti-Retroviral Agents; Chemistry, Pharmaceutical; Drug Design; Drug Industry; HIV; HIV Reverse Transcriptase; Humans; Models, Chemical; Models, Molecular; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Thiazoles; Thymine; Triazoles

2006
Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.
    Biochemical pharmacology, 2000, Nov-01, Volume: 60, Issue:9

    Topics: Amino Acid Substitution; Drug Design; Drug Resistance, Microbial; HIV; HIV Reverse Transcriptase; Humans; Models, Molecular; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiazoles; Triazoles

2000

Trials

2 trial(s) available for triazoles and HIV

ArticleYear
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:9

    Topics: Adaptive Immunity; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Dendritic Cells; Female; HIV; HIV Infections; Humans; Immunity, Innate; Lymphocyte Subsets; Male; Maraviroc; Prospective Studies; Triazoles

2015
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    The Journal of infectious diseases, 2009, Jun-01, Volume: 199, Issue:11

    Topics: Adult; Aged; Cyclohexanes; Double-Blind Method; Female; Genotype; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Least-Squares Analysis; Male; Maraviroc; Middle Aged; Patient Selection; Phenotype; Placebos; Triazoles; Viral Load; Young Adult

2009

Other Studies

22 other study(ies) available for triazoles and HIV

ArticleYear
Administration of Crushed Doravirine via Nasojejunal Feeding Tube in a Patient With Treatment-Experienced Human Immunodeficiency Virus.
    Journal of pharmacy practice, 2023, Volume: 36, Issue:4

    Topics: HIV; Humans; Intubation, Gastrointestinal; Pyridones; Triazoles

2023
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:11

    Topics: Cyclohexanes; DNA, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Maraviroc; Treatment Outcome; Triazoles; Viral Tropism

2013
The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:9

    Topics: Adult; Age Factors; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Middle Aged; Multivariate Analysis; Retrospective Studies; RNA, Viral; Treatment Outcome; Triazoles; Viral Load

2015
Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
    Antiviral research, 2015, Volume: 121

    Topics: Adult; Aged; Anti-HIV Agents; Cyclohexanes; Female; Genotype; Genotyping Techniques; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult

2015
Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    EBioMedicine, 2015, Volume: 2, Issue:9

    Topics: Acrylates; Active Transport, Cell Nucleus; Animals; Apoptosis; Base Sequence; Cell Cycle Checkpoints; Cell Line; Cell Nucleus; CRISPR-Cas Systems; Exportin 1 Protein; Female; HIV; Humans; Karyopherins; Lymphoma, AIDS-Related; Mice, Nude; Molecular Sequence Data; Molecular Targeted Therapy; NF-kappa B; Protein Binding; Receptors, Cytoplasmic and Nuclear; Reproducibility of Results; rev Gene Products, Human Immunodeficiency Virus; RNA, Messenger; RNA, Viral; Triazoles; Tumor Suppressor Protein p53; Virus Replication; Xenograft Model Antitumor Assays

2015
No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
    AIDS (London, England), 2016, Mar-27, Volume: 30, Issue:6

    Topics: Anti-HIV Agents; Cyclohexanes; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Maraviroc; Selection, Genetic; Triazoles; Viral Tropism

2016
Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry letters, 2016, Aug-01, Volume: 26, Issue:15

    Topics: Anti-HIV Agents; Click Chemistry; Cyclization; Dose-Response Relationship, Drug; HIV; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles

2016
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Cyclohexanes; HIV; HIV Fusion Inhibitors; Humans; Inhibitory Concentration 50; Maraviroc; Triazoles; Viral Tropism; Virology

2016
Application of the Triazolization Reaction to Afford Dihydroartemisinin Derivatives with Anti-HIV Activity.
    Molecules (Basel, Switzerland), 2017, Feb-17, Volume: 22, Issue:2

    Topics: Amines; Anti-HIV Agents; Artemisinins; Catalysis; Cell Line; HIV; Humans; Inhibitory Concentration 50; Ketones; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Triazoles

2017
Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT).
    Xenobiotica; the fate of foreign compounds in biological systems, 2008, Volume: 38, Issue:10

    Topics: Animals; Brain; Cyclohexanes; Drug Evaluation, Preclinical; Feasibility Studies; HIV; HIV Fusion Inhibitors; Intestinal Mucosa; Lymphoid Tissue; Male; Maraviroc; Rats; Tissue Distribution; Triazoles

2008
[Introduction. A brief history of AIDS].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; History, 20th Century; History, 21st Century; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles

2008
An investigation into the anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U) and 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
    Organic & biomolecular chemistry, 2009, Jun-21, Volume: 7, Issue:12

    Topics: Amides; Anti-HIV Agents; Cathepsins; Dideoxynucleosides; HIV; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Organophosphorus Compounds; Phosphoric Acids; Triazoles

2009
Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, HIV; Triazoles; Viral Load; Young Adult

2009
Tether influence on the binding properties of tRNALys3 ligands designed by a fragment-based approach.
    Organic & biomolecular chemistry, 2010, Mar-07, Volume: 8, Issue:5

    Topics: Binding Sites; HIV; HIV Infections; Ligands; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Reverse Transcription; RNA, Transfer, Amino Acyl; RNA, Viral; Triazoles

2010
Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, Volume: 17, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genome, Viral; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Receptors, HIV; Sequence Analysis, DNA; Sequence Analysis, RNA; Triazoles; Viral Load

2011
TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:12

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Middle Aged; Triazoles; Viral Tropism; Virus Cultivation

2010
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
    Journal of pharmacokinetics and pharmacodynamics, 2011, Volume: 38, Issue:1

    Topics: Algorithms; Computer Simulation; Cyclohexanes; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Models, Statistical; Research Design; Software; Triazoles; Viral Load

2011
Penicillium marneffei infection presenting as vulv-ulcer in an HIV-infected woman.
    European journal of medical research, 2011, Sep-12, Volume: 16, Issue:9

    Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Diagnosis, Differential; Female; HIV; HIV Infections; Humans; Mycoses; Penicillium; Pyrimidines; Triazoles; Ulcer; Voriconazole; Vulvar Diseases; Young Adult

2011
Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:1

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Salvage Therapy; Treatment Failure; Triazoles

2013
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.
    Nucleic acids research, 2013, Jan-07, Volume: 41, Issue:1

    Topics: Anti-HIV Agents; Azepines; Cell Cycle Proteins; Cyclin-Dependent Kinase 9; HeLa Cells; HIV; Humans; Jurkat Cells; Nuclear Proteins; Phorbol Esters; Phosphorylation; Positive Transcriptional Elongation Factor B; Promoter Regions, Genetic; Ribonucleoproteins, Small Nuclear; RNA Polymerase II; tat Gene Products, Human Immunodeficiency Virus; Transcription Factors; Transcriptional Activation; Transcriptional Elongation Factors; Triazoles; Virus Latency

2013
Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy.
    AIDS (London, England), 2008, Apr-23, Volume: 22, Issue:7

    Topics: Antifungal Agents; Carcinoma, Squamous Cell; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrimidines; Skin Neoplasms; Triazoles; Voriconazole

2008
Researchers explore new anti-HIV agents.
    JAMA, 2002, Apr-03, Volume: 287, Issue:13

    Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclic N-Oxides; Drugs, Investigational; Enfuvirtide; Furans; HIV; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Oximes; Peptide Fragments; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles

2002